On July 23, 2024, Gland Pharma Limited, a company specialising in generic injectable drugs, announced via a stock exchange filing that it has received tentative approval from the USFDA (US Food and Drug Administration ) for its Latanoprostene Bunod Ophthalmic Solution, 0.024%. This product is considered equivalent to Bausch & Lomb Inc.’s Vyzulta® Ophthalmic Solution, …


